




Searching News Database: Rebif
HSMN NewsFeed - 7 Dec 2017
John Walsh, M.D. Joins EMD Serono as Vice President of Neurology & Immunology, US Medical Affairs
John Walsh, M.D. Joins EMD Serono as Vice President of Neurology & Immunology, US Medical Affairs
HSMN NewsFeed - 28 Jun 2016
FDA Grants Priority Review for Genentech’s OCREVUS(TM) (ocrelizumab) Biologics License Application
FDA Grants Priority Review for Genentech’s OCREVUS(TM) (ocrelizumab) Biologics License Application
HSMN NewsFeed - 21 Mar 2014
Genzyme’s Lemtrada(TM) Approved in Brazil for Treatment of Multiple Sclerosis
Genzyme’s Lemtrada(TM) Approved in Brazil for Treatment of Multiple Sclerosis
HSMN NewsFeed - 30 Dec 2013
Genzyme Receives Complete Response Letter from FDA on Lemtrada(TM) (alemtuzumab) Application
Genzyme Receives Complete Response Letter from FDA on Lemtrada(TM) (alemtuzumab) Application
HSMN NewsFeed - 19 Dec 2013
Genzyme’s Lemtrada(TM) Approved in Australia for Treatment of Multiple Sclerosis
Genzyme’s Lemtrada(TM) Approved in Australia for Treatment of Multiple Sclerosis
HSMN NewsFeed - 13 Dec 2013
Genzyme’s Lemtrada(TM) Approved in Canada for Treatment of Multiple Sclerosis
Genzyme’s Lemtrada(TM) Approved in Canada for Treatment of Multiple Sclerosis
HSMN NewsFeed - 17 Sep 2013
European Commission Approves Genzyme’s Multiple Sclerosis Treatment Lemtrada(TM) (alemtuzumab)
European Commission Approves Genzyme’s Multiple Sclerosis Treatment Lemtrada(TM) (alemtuzumab)
HSMN NewsFeed - 28 Jun 2013
Genzyme Receives Positive CHMP Opinion for LEMTRADA(TM) (alemtuzumab) in Europe
Genzyme Receives Positive CHMP Opinion for LEMTRADA(TM) (alemtuzumab) in Europe
HSMN NewsFeed - 28 Jan 2013
Genzyme’s LEMTRADA(TM) (alemtuzumab) Application for MS Accepted for Review by the FDA
Genzyme’s LEMTRADA(TM) (alemtuzumab) Application for MS Accepted for Review by the FDA
HSMN NewsFeed - 14 Nov 2011
Genzyme Announces Successful Phase III Results for Alemtuzumab (LEMTRADA(TM*)) in Multiple Sclerosis
Genzyme Announces Successful Phase III Results for Alemtuzumab (LEMTRADA(TM*)) in Multiple Sclerosis
HSMN NewsFeed - 1 Jun 2009
UK's NICE Recommends Use of Erbitux for Metastatic Colorectal Cancer Patients
UK's NICE Recommends Use of Erbitux for Metastatic Colorectal Cancer Patients
HSMN NewsFeed - 24 Feb 2009
Merck Serono and Ambrx Expand Collaboration Through ARX424 Multiple Sclerosis Drug Development Alliance
Merck Serono and Ambrx Expand Collaboration Through ARX424 Multiple Sclerosis Drug Development Alliance
HSMN NewsFeed - 19 Feb 2009
European Medicines Agency Recommends Suspension of Marketing Authorization for Raptiva(R)
European Medicines Agency Recommends Suspension of Marketing Authorization for Raptiva(R)
HSMN NewsFeed - 5 Aug 2008
Marinus Pharmaceuticals Appoints John Krayacich as President and Chief Executive Officer
Marinus Pharmaceuticals Appoints John Krayacich as President and Chief Executive Officer
HSMN NewsFeed - 10 Jun 2008
Merck Serono Strengthens its Prescription Medicines Portfolio in Latin America
Merck Serono Strengthens its Prescription Medicines Portfolio in Latin America
HSMN NewsFeed - 5 Jun 2008
Merck Serono Announces Initiation of Second Phase II/III Clinical Study of Atacicept in Lupus
Merck Serono Announces Initiation of Second Phase II/III Clinical Study of Atacicept in Lupus
HSMN NewsFeed - 16 Apr 2008
Merck Announces Planned Investment of $50 Million in Research Center in the US
Merck Announces Planned Investment of $50 Million in Research Center in the US
HSMN NewsFeed - 7 Nov 2007
BRIGHT Results Show Less Pain and Higher Patient Satisfaction with Betaseron(R) than with Rebif(R)
BRIGHT Results Show Less Pain and Higher Patient Satisfaction with Betaseron(R) than with Rebif(R)
HSMN NewsFeed - 30 Jan 2007
Merck Serono Launches easypod(R), First Electronic Growth Hormone Injection Device
Merck Serono Launches easypod(R), First Electronic Growth Hormone Injection Device
HSMN NewsFeed - 16 Jan 2007
Merck Serono Announces Positive Results From Phase III Diet Study of Phenoptin for Phenylketonuria
Merck Serono Announces Positive Results From Phase III Diet Study of Phenoptin for Phenylketonuria
HSMN NewsFeed - 16 Jan 2007
Merck Serono Completes Patient Enrollment in CLARITY Phase III Pivotal Clinical Trial of Oral Cladribine
Merck Serono Completes Patient Enrollment in CLARITY Phase III Pivotal Clinical Trial of Oral Cladribine
HSMN NewsFeed - 16 Oct 2006
Serono and Newron Announce Global Development and Commercialization Agreement for Safinamide
Serono and Newron Announce Global Development and Commercialization Agreement for Safinamide
HSMN NewsFeed - 21 Sep 2006
Serono's Oral Cladribine for the Treatment of Multiple Sclerosis Awarded Fast Track Status by FDA
Serono's Oral Cladribine for the Treatment of Multiple Sclerosis Awarded Fast Track Status by FDA
HSMN NewsFeed - 10 Jul 2006
European Commission Approves Revision of Therapeutic Indication for Rebif(R)
European Commission Approves Revision of Therapeutic Indication for Rebif(R)
HSMN NewsFeed - 4 Apr 2006
Serono Submits New Formulation of Rebif(R) for Approval in the United States and in Europe
Serono Submits New Formulation of Rebif(R) for Approval in the United States and in Europe
HSMN NewsFeed - 15 Mar 2006
BioMarin and Serono Announce Positive Results From Phase 3 Clinical Study of Phenoptin for PKU
BioMarin and Serono Announce Positive Results From Phase 3 Clinical Study of Phenoptin for PKU
HSMN NewsFeed - 24 Jan 2006
Serono's Gonal-f(R) Approved in Japan for the Treatment of Male Hypogonadotropic Hypogonadism
Serono's Gonal-f(R) Approved in Japan for the Treatment of Male Hypogonadotropic Hypogonadism
Additional items found! 74

Members Archive contains
74 additional stories matching:
Rebif
(Password required)
Rebif
(Password required)